propionate 通过调节铁的稳态来缓解大肠炎,以抑制铁和巨分化
Ting Yao1, Xiangmin Dong1, Jiawen Lv1
1State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Rd., Hangzhou City 310003, China.
酸有效地治疗性结肠炎 (UC) 通过减少炎症和ferroptosis. 它促进肠道愈合并调节铁含量,为这种炎症性肠病提供了一个有前途的治疗策略.
科学领域:
- 胃肠病学 胃肠病学
- 细胞生物学 细胞生物学
- 生物化学 生物化学
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症性肠病,治疗选择不足.
- 脂质过氧化驱动的细胞死亡形式铁,在UC病变发生过程中发挥作用.
- 在UC中,酸是一种短链脂肪酸的治疗潜力尚不清楚.
研究的目的:
- 为了调查ferroptosis在UC中的作用.
- 在实验性结肠炎模型中评估酸的治疗疗效.
- 阐明酸在UC中的作用的基本机制.
主要方法:
- 在UC患者数据集 (GEO数据库) 中对铁亡标记物的分析.
- 建立实验性大肠炎的小鼠模型.
- 在酸盐治疗后评估炎症,铁灭菌标志物和铁的稳定性.
- 研究基因表达 (TFR1,FTH1,HIF-1α) 和巨细胞极化.
主要成果:
- 在UC患者的结肠组织和大肠炎模型中证实了铁.
- 酸治疗缓解了UC症状,减少了促炎性细胞因子,改善了铁的稳定性.
- 高剂量酸 (400毫米) 显著抑制了铁亡并促进了肠道上皮的再生.
- 酸通过HIF-1α调节了TFR1和FTH1的表达,并促进了M2巨细胞的两极分化.
结论:
- 氨酸在性结肠炎中显示出显著的治疗潜力.
- 它通过调节铁平衡,抑制铁亡,促进上皮细胞修复来起作用.
- 该机制涉及HIF介导的TFR1/FTH1调节和巨细胞分化调节.
更多相关视频
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
04:01Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
Published on: March 15, 2024
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Drugs for Treatment of Constipation-Predominant IBS
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
